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Abstract—Acute phosphodiesterase 5A inhibition by sildenafil or EMD360527/5 promoted profound inhibition of the
cardiac Na1/H1 exchanger (NHE-1), detected by the almost null intracellular pH recovery from an acute acid load
(ammonium prepulse) in isolated papillary muscles from Wistar rats. Inhibition of phosphoglycerate kinase-1 (KT5823)
restored normal NHE-1 activity, suggesting a causal link between phosphoglycerate kinase-1 increase and NHE-1
inhibition. We then tested whether the beneficial effects of NHE-1 inhibitors against the deleterious postmyocardial
infarction (MI) remodeling can be detected after sildenafil-mediated NHE-1 inhibition. MI was induced by left anterior
descending coronary artery ligation in Wistar rats, which were randomized to placebo or sildenafil (100 mg kg21 day21)
for 6 weeks. Sildenafil significantly increased left ventricular phosphoglycerate kinase-1 activity in the post-MI group
without affecting its expression. MI increased heart weight/body weight ratio, left ventricular myocyte cross-sectional
area, interstitial fibrosis, and brain natriuretic peptide and NHE-1 expression. Sildenafil blunted these effects. Neither
a significant change in infarct size nor a change in arterial or left ventricular systolic pressure was detected after
sildenafil. MI decreased fractional shortening and the ratio of the maximum rate of rise of LVP divided by the pressure
at the moment such maximum occurs, effects that were prevented by sildenafil. Intracellular pH recovery after an acid
load was faster in papillary muscles from post-MI hearts (versus sham), whereas sildenafil significantly inhibited NHE-1
activity in both post-MI and sildenafil-treated sham groups. We conclude that increased phosphoglycerate kinase-1
activity after acute phosphodiesterase 5A inhibition blunts NHE-1 activity and protects the heart against post-MI
remodeling and dysfunction. (Hypertension. 2007;49:1095-1103.)
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The Na1/H1 exchanger isoform 1 (NHE-1) is expressed atsignificant levels in heart tissue.1 Several experimental
studies performed after the seminal work by Karmazyn2 have
shown that NHE-1 activity plays a critical role in ischemia/
reperfusion injury and after myocardial infarction (MI).1,3–5
Different compounds that inhibit the exchanger dramatically
reduce infarct size (IS) and improve function and postinfarc-
tion hypertrophy.1,5 NHE-1 inhibition seems to be beneficial
even if it is started 2 or 4 weeks after MI,5 suggesting that the
protection is independent of IS. In a canine heart infarction
model, NHE-1 inhibition was significantly more efficacious,
protecting against prolonged ischemia than any other maneu-
ver, including ischemic preconditioning.6 These findings led
to the clinical testing of selective NHE-1 inhibitors as
potential interventions for cardiac protection in acute coro-
nary syndromes. Although a small clinical trial with patients
with acute MI undergoing percutaneous-transluminal coro-
nary angioplasty demonstrated beneficial effects,7 2 larger
trials, The Guard During Ischemia Against Necrosis
(GUARDIAN)8 and the sodium-hydrogen EXchange inhibi-
tion to Prevent coronary Events in acute cardiac conDITIONs
(EXPEDITION)9 did not provide conclusive results. In
GUARDIAN, only a subset of patients undergoing high-risk
coronary artery bypass graft surgery showed beneficial ef-
fects after NHE-1 inhibition.10 In the EXPEDITION trial,
NHE-1 inhibition reduced the incidence of MI after coronary
artery bypass graft surgery but increased the overall rate of
cerebrovascular events, which resulted in early discontinua-
tion of the study.9
A recent publication suggested that inhibition of the
exchanger only after its activation by acidosis, but not during
its basal function, may present therapeutic advantages.11
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Although inhibition of the NHE-1 only after critical situations
and not under basal conditions seems unrealistic, it was
reported that inhibition of p90 ribosomal S6 kinase, which
phosphorylates the cytosolic tail of the NHE-1, decreased
agonistic activated NHE-1 function without inhibiting its
basal homeostatic function.11 More interestingly, this inhibi-
tion was accompanied by beneficial effects.11
Because an increase in protein kinase G (PKG) activity in
renal mesangial cells inhibited NHE activity only after an
acidic load but not in basal conditions,12 we hypothesized that
the same pattern may be reproduced in myocardial tissue by
chronic inhibition of the cGMP-catabolizing enzyme phos-
phodiesterase 5A (PDE5A). We will provide evidence that
NHE-1 inhibition, after an acidic load but not under basal
conditions, can be obtained by PDE5A inhibition and that this
inhibition has beneficial effects on cardiac remodeling and
function after experimental MI in the rat heart.
Methods
The investigation conforms with the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health Publication No.
85-23, revised 1996).
Experimental MI
MI was induced in 3- to 4 month-old male Wistar rats as described
previously.13 Briefly, the rats were anesthetized (50 mg/kg of sodium
pentobarbital, IP), then intubated and ventilated with room air using
a positive-pressure respirator (Model 680, Harvard). A left thoracot-
omy was performed via the fourth intercostal space, and the lungs
retracted to expose the heart. The left anterior descending coronary
artery was ligated with a 7-0 silk suture near its origin. Acute
ischemia was deemed successful when the anterior wall of the left
ventricle became cyanotic. The lungs were inflated by increasing
positive end-expiratory pressure, and the thoracotomy site was
closed in layers. Immediately after surgery, rats were randomized to
receive placebo (MI group) or sildenafil (SIL) 100 mg kg21 day21
(MI1SIL group) orally through drinking water for 6 weeks. Another
group of rats underwent sham ligation; the procedure was similar,
but the suture was not tightened around the coronary artery. Shams
were also randomly assigned to receive SIL 100 mg kg21 day21
(SHAM1SIL group) or placebo (SHAM group) for 6 weeks. SIL
dosage was selected based on a previous report.14
Echocardiographic Examination
Rats were monitored echocardiographically under light anesthesia
(35 mg/kg of pentobarbital sodium IP). 2D targeted M-mode
tracings were recorded with a 7-MHz transducer. Left ventricular
(LV) end diastolic and systolic internal diameters (LVEDd and
LVESd, respectively) were measured using the American Society
of Echocardiography leading-edge method from $3 cardiac
cycles.15 Endocardial fractional shortening was calculated as:
(LVEDd2LVESd)/LVEDd3100.
In Vivo Determination of LV Pressure
Rats were lightly anesthetized (35 mg/kg of pentobarbital sodium
IP), placed on a warm pad (37°C), and a 14-gauge catheter was
placed in the trachea for room air ventilation. A fluid-filled catheter
(Pebax 03) advanced to the left ventricle via the right carotid artery
was used for in vivo LV pressure measurement, using a technique
validated previously by Wang et al.16 The ratio of the maximum rate
of rise of LV pressure divided by the pressure at the moment such
maximum occurs was determined as an index of inotropism.
Histological and Morphometric Analysis
For IS determinations, 3- to 4-mm-width cross-sections of each heart
were cut from apex to base. The tissue slides were processed for
paraffin embedding and stained with Masson trichrome. The IS was
calculated as the mean percentage of LV epicardial and endocardial
circumference occupied by the scar tissue averages for all of the
ventricular levels.17 LV cardiomyocyte cross-sectional area (CSA)
was determined in hematoxylin/eosin-stained slides from 80 to 90
myocytes from each heart as described previously.18,19 Cardiomyo-
cytes were accepted for quantitative analysis if their cross-sections
contain a centrally located nucleus and the cellular membrane was
unbroken. The interstitial fibrosis was assessed in picrosirius red-
stained tissue slides. The percentage of collagen was calculated as
the sum of collagen areas divided by the total LV area (myocytes1
collagen).19
Brain Natriuretic Peptide Expression
Brain natriuretic peptide (BNP) expression was assessed by
real-time RT- PCR and normalized to GAPDH following a
procedure described previously.20 Briefly, total LV RNA was
extracted using the RNeasy kit (Qiagen) and reverse transcribed
using the Omniscript RT kit (Qiagen). A dilution of the resulting
cDNA was used to quantify the relative mRNA content (iCycler iQ
real-time PCR detection system, Bio-Rad) using appropriate primers
and SYBR Green as the fluorescent probe. Primer sequences were:
GAPDH forward primer 59-GGGTGTGAACCACGAGAAAT-39,
reverse primer 59-CCACAGTCTTCTGAGTGGCA-39; BNP for-
ward primer 59-CCCAGATGATTCTGCTCCTG-39, reverse primer
59-TTCTGCATCGTGGATTGTTC-39.
NHE-1 Protein Expression
NHE-1 expression was assessed as described previously21 by immu-
noblot analysis of LV membrane–enriched fractions using a rabbit
polyclonal antibody for NHE-1 (kindly donated by Dr M. Donowitz,
Johns Hopkins University, Baltimore, Md). Immunoreactive protein
detection was performed by chemiluminescence (Amersham), and
signals were quantified by densitometric analysis.
Determination of PKG-1 Activity and
Protein Expression
A previously described technique that uses phosphotransfer of [32Pi]
from [g-32P]ATP into a synthetic heptapeptide was used to determine
PKG-1 activity.22 The assay consisted of 50 mL of a mixture
composed of 20 mmol/L of Tris, 200 mmol/L of ATP (30 000 cpm
mL21 assay mixture), 136 mg mL21 of phosphoreceptor heptapeptide
(RKRSRAE, Peninsula Laboratories Inc), 20 mmol/L of magnesium
acetate, 100 mmol/L of 3-isobutyl-1-methylxanthine, and 1 mmol/L
of synthetic peptide inhibitor of PKA (Peninsula Laboratories Inc;
pH 7.4). To this mixture, 10 mL of cardiac homogenate fraction was
added, and the reaction was incubated at 30°C for 10 minutes. The
reaction was terminated by spotting 40 mL of the mixture on P81
phosphocellulose paper (Whatman). PKG-1 activity was expressed
as femtomol of phosphate per minute per microgram of protein.
PKG-1 protein expression was determined by Western blot immu-
noanalysis with rabbit polyclonal antibody (Santa Cruz Biotechnol-
ogy) and mouse monoclonal antibody for actin (Sigma). Immuno-
detection of the primary antibody was performed with peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence
reaction system (Amersham). Densitometric analysis of PKG-1
protein was referred to that of actin.
Measurement of Intracellular pH, Determination
of NHE-1 Activity, and Intrinsic Buffer Capacity
Intracellular pH (pHi) was measured in isolated LV papillary muscles
following a previously described 29-79-bis(2 carboxyethyl)-5,6-
carboxyfluorescein-epifluorescence technique.23 The NHE-1 activity
was assessed by the Na1-dependent pHi recovery from an ammo-
nium prepulse-induced acute acid load.24 The experiments were
performed in the nominal absence of bicarbonate to assure that the
pHi recovery after Na1 readdition was because of NHE-1 activation.
Intrinsic buffer capacity (bi) was determined as described
previously.24
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Statistical Analysis
Results are presented as mean6SEM. Statistical analysis was per-
formed using the Student t test or 1-way ANOVA followed by the
Student–Newman–Keuls test, when necessary. P,0.05 was consid-
ered significant.
Results
NHE-1 activity was assessed in isolated papillary muscles
based on the Na1-dependent initial rate of pHi recovery from
an acute and sustained acid load. Because the experiments
were performed in the nominal absence of bicarbonate, the
recovery of pHi after the acidic load was exclusively because
of NHE-1 activation. Given that the maximal-induced acid-
ification and bi were similar in all of the groups (Table 1),
the maximal velocity of pHi recovery (maxdpHi/dt) was used
as an index of NHE-1 activity (because JH15 dpHi/dt z bi;
in the absence of changes in bi among groups, dpHi/dt
directly reflects JH1). NHE-1 activity was tested before and
after PDE5A inhibition by SIL (1 mmol/L) added to the
superfusate '40 minutes before the onset of the acidic
challenge. Interestingly, SIL did not affect basal pHi
(7.2260.03 versus 7.2360.02, before and after SIL, re-
spectively; n55) but significantly blunted NHE-1 activity
after the sustained acidic load (Figure 1). For comparative
purposes, the results obtained with the well-known NHE-1
inhibitory compound cariporide are also shown (Figure 1).
As expected, cariporide blunted the pHi recovery signifi-
cantly after the acidic load, but, in contrast to the PDE5A
inhibitor, it also affected basal pHi (7.2460.03 versus
6.9660.02, before and after cariporide, respectively; n53;
P,0.05). The results obtained with SIL can be reproduced
by another PDE5A inhibitor, EMD360527/5 (0.1 mmol/L),
as shown in Figure 1.
The fact that a similar decrease in the NHE-1 activity
was obtained by using 2 structurally different PDE5A
inhibitors suggests that increased PKG-1 activity might be
responsible for this effect. This was confirmed by using the
PKG-1 inhibitor KT5823 (1 mmol/L) in experiments in
which the effect of this compound on NHE-1 activity after
acute PDE5A inhibition by SIL was examined. Under
these conditions, maxdpHi/dt was not found to be statisti-
cally different from controls (Figure 2), supporting the
notion that PKG-1 inhibition blunted the inhibitory effect
of SIL on NHE-1. KT5823 alone did not alter maxdpHi/dt
significantly (Figure 2).
According to previous experimental evidence, the use of
NHE-1 inhibitors, or even the genetic ablation of the ex-
changer, promotes protection not only on ischemia/reperfu-
sion injury but also after coronary artery occlusion influenc-
ing post-MI remodeling.1,25,26 Therefore, we hypothesized
that NHE-1 inhibition by PDE5A inhibitors should also
protect the heart in a similar way to that described for NHE-1
inhibition by other compounds.3,5 Thus, we decided to ex-
plore whether the protection described for NHE-1 inhibitors
when treatment started after coronary occlusion5 would be
mimicked by chronic SIL treatment. Inhibition and reversal
of MI-induced hypertrophy, fibrosis, and function have been
reported for NHE-1 inhibitors even when the treatment
started 2 or 4 weeks after coronary occlusion.5 On the other
hand, we have reported that NHE-1 inhibition was able to
regress hypertensive hypertrophy and fibrosis in rats,27–29 and
Takimoto et al14 reported that SIL was able to regress
pressure overload–induced hypertrophy.
SIL treatment for 6 weeks did not modify blood pressure,
LV systolic pressure, or LV end diastolic pressure signifi-
cantly (which is also in line with the report of Takimoto et
al14; Table 2). IS was not different between groups (MI:
40610%, n54, and MI1SIL: 3167%, n54). An increased
TABLE 1. Maximal-Induced Intracellular Acidification After
Ammonium Washout and bi for All of the Experimental Groups
Experimental Groups pHi bi, mmol/L
Control (n56) 6.7460.02 28.260.9
SIL (n55) 6.7660.04 27.361.6
Cariporide (n53) 6.7060.02 29.460.7
EMD360527/5 (n54) 6.7460.02 28.060.7
SIL1KT5823 (n54) 6.7260.03 28.660.9
KT5823 (n54) 6.7560.01 27.860.4
Figure 1. Acute PDE5A inhibition by SIL or EMD360527/5 (EMD)
prevented NHE-1 activity. To appreciate the magnitude of NHE
inhibition after PDE5A inhibition, results obtained with the widely
known NHE-1 inhibitor cariporide are also shown. Typical
experiments plus their best exponential fit for each group are
displayed in A, and the corresponding pooled data for the
maxdpHi/dt are displayed in B. *P,0.05 vs control.
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heart weight/body weight ratio was detected 6 weeks after
coronary artery ligation, which suggested that the ischemic
insult promoted myocardial hypertrophy in the surviving
ventricular zone; this effect was attenuated significantly by
SIL treatment (in mg g21): SHAM, 2.5260.07, n57; MI,
3.3060.20, n55; MI1SIL, 2.8560.04, n55; and
SHAM1SIL, 2.3660.04, n55 (P,0.05 MI versus all of the
other groups and MI1SIL versus SHAM and SHAM1SIL).
Histological analysis of the hearts lent support to these
findings by showing a significant increase in the LV myocyte
CSA and collagen content in the MI group; these effects were
blunted significantly by SIL treatment (Figure 3). On the
other hand, SIL treatment of sham rats did not affect cardiac
fibrosis or myocyte CSA compared with nontreated shams
(Figure 3).
Echocardiographic analysis 6 weeks after MI revealed a
slight but nonsignificant increase in the LVEDd (Figure 4A)
and a significant increase in LVESd (Figure 4B) compared
with the SHAM and the SHAM1SIL groups. SIL treatment
on MI animals did not modify LVEDd (Figure 4A) but
prevented the increase in LVESd (Figure 4B). The functional
correlation of these findings was a significant decrease in
endocardial fractional shortening in the post-MI group that
was prevented completely by SIL treatment (Figure 4C).
Thus, MI decreased the ratio of the maximum rate of rise of
LV pressure divided by the pressure at the moment that such
maximum occurs, and SIL treatment restored it toward
normal (Figure 4D). These parameters were not affected by
SIL in the treated shams (Figure 4).
Myocardial expression of BNP, another index of cardiac
hypertrophy, and NHE-1 were also analyzed after MI with
and without SIL treatment. MI increased both BNP and
NHE-1 expression, and these effects were blunted signifi-
cantly by SIL treatment (Figure 5A and 5B). Hearts from
SIL-treated shams did not show any significant change in
BNP or NHE-1 expressions (Figure 5A and 5B).
The upregulation of NHE-1 expression after MI detected
by us in the present study was also shown recently by Chen
et al,5 who reported that inhibition of the exchanger normal-
izes its expression and improves cardiac function and remod-
eling without affecting IS, in agreement with our results.
Interestingly, our results show that SIL treatment after MI,
similar to NHE-1 inhibition by EMD87580,5 protected the
heart against postinfarction hypertrophy and dysfunction and
diminished the augmented BNP and NHE-1 expressions
(Figures 3 to 5).
SIL treatment increased LV PKG-1 activity significantly
after MI (Table 3). However, nonsignificant changes in
PKG-1 activity were detected after SIL treatment in the
absence of MI. Similar findings were reported by Takimoto et
al.14 LV PKG-1 expression was not significantly different
among groups (Table 3).
To further explore the possible causal link between PDE5A
inhibition–NHE-1 inhibition and post-MI protection, we eval-
uated NHE-1 activity in papillary muscles isolated from
hearts explanted from all of the experimental groups after the
6-week follow up period. The Na1-dependent pHi recovery
from an acute and sustained acid load induced by an ammo-
nium prepulse was analyzed. Basal pHi was similar in all of
Figure 2. PKG-1 inhibition by KT5823 (KT) after SIL treatment
restored normal NHE-1 activity. KT5823 alone did not alter
maxdpHi/dt. For the sake of comparison, the control experiments
of Figure 1 are also shown here. As in Figure 1, typical
experiments plus their best exponential fit for each group are
displayed in A, and the corresponding pooled data for the
maxdpHi/dt are displayed in B.
TABLE 2. In Vivo Determined Hemodynamic Parameters
Experimental Groups LVEDP, mm Hg LVSP, mm Hg 1dP/dt, mm Hg/s 2dP/dt, mm Hg/s Aortic Pressure, mm Hg
SHAM (n57) 4.761.0 99.467.3 65416690 248576674 9967/5865
MI (n57) 4.161.2 87.369.6 45756987 235216609 87610/5068
MI1SIL (n55) 7.660.8 88.266.8 55016600 236296372 8867/4965
SHAM1SIL (n55) 6.361.7 104.467.7 50456748 236516465 10468/4666
LVEDP indicates left ventricular end diastolic pressure; LVSP, left ventricular systolic pressure, max1dP/dt, maximum rate of LVP
rise; 2dP/dt, maximum rate of LVP decline; Aortic pressure, systolic/diastolic.
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the groups: SHAM, 7.2460.02, n55; MI, 7.2560.01, n55;
MI1SIL, 7.2160.02, n55; and SHAM1SIL, 7.2560.01,
n54. The maximal-induced acidification and bi were also
similar in all of the groups (Table 4). Papillary muscles from
post-MI hearts showed enhanced NHE-1 activity detected by
an '4-fold increase in maxdpHi/dt after the acidic load
compared with SHAM (Figure 6). Interestingly, SIL treat-
ment prevented the augmented NHE-1 activity in post-MI
hearts and induced a dramatic inhibition of the exchanger
(Figure 6), an effect comparable only to that obtained by
other authors and ourselves with high doses of specific
NHE-1 inhibitors30 (Figure 1). On the other hand, and in
agreement with the results obtained after acute PDE5A
inhibition (Figure 1), muscles from chronically SIL-treated
shams also showed profound NHE-1 inhibition (Figure 6).
Discussion
We report here a previously unknown effect of PDE5A
inhibition by SIL on myocardial NHE-1 activity. This inhi-
bition was obtained also by another structurally different and
highly selective PDE5A inhibitor, EMD360527/5. Moreover,
the inhibition of the NHE-1 activity after the sustained
acidosis was blunted by specific PKG inhibition with
KT5823, suggesting that increased PKG-1 activity might be
responsible for the NHE-1 inhibition.
Although inhibition of cardiac NHE-1 by PKG was previ-
ously unknown, PKG-mediated NHE-1 inhibition has been
already described in mesangial cells12 and in ocular nonpig-
mented ciliary epithelium.31 In addition, it has been reported
that an increase in the cGMP-PKG pathway can decrease the
activity of other NHE isoforms.32,33
Figure 3. A, Original histological sections showing the CSA of LV myocytes (top) and the LV collagen volume fraction (CVF; bottom) for
(from left to right): SHAM, MI, MI1SIL, and SHAM1SIL group. B, Overall results for CSA (left) and CVF (right) for the 4 experimental
groups. MI increased myocyte CSA and CVF compared with SHAM and SIL treatment blunted these effects significantly. SIL alone
(SHAM1SIL group) did not have any significant effect on either CSA or CVF. *P,0.05 vs all of the other groups.
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Interestingly, and in contrast to other NHE-1 inhibitory
compounds, both PDE5A inhibitors used here inhibited the
NHE-1 only after an acidic load without modifying basal pHi,
thus preserving the important “housekeeping” function of the
exchanger. A similar differential effect on basal and stimu-
lated NHE-1 activity was reported recently after NHE-1
activation by phosphorylation through p90 ribosomal S6
kinase.11 This report called attention to the potential thera-
peutic advantages of using NHE-1 inhibitory compounds that
selectively blunt the exchanger activity only after an acidic
challenge and not under basal conditions. The level of
phosphorylation and activity of the exchanger probably re-
sults from a permanent equilibrium between kinase and
phosphatase activities. The possible participation of the
Ras/Raf/mitogen activated protein kinase kinase/extracellular
signal regulated kinase/p90 ribosomal S6 kinase pathway and
of protein phosphatases, such as PP1 and PP2A, in the
PDE5A inhibition-induced decrease in NHE-1 activity de-
serves further investigation. We could speculate that an
increased PKG-1 activity may decrease NHE-1 activity by a
direct phosphorylation of the exchanger. However, we are not
aware of studies demonstrating the existence of consensus
sites for PKG-1 in the NHE-1. We can speculate also about
possible changes in the activity of the exchanger independent
of the cytosolic tail phosphorylation. Deletion of the phos-
phorylation sites at the C-terminal seems to decrease only
50% of the growth factor–mediated increased activity of the
exchanger.34 In connection with this, the phosphorylation
state of “accessory” proteins may regulate NHE-1 activity
indirectly without affecting the NHE-1 phosphorylation itself.
In this regard, 2 calcineurin-b homologue proteins associated
with NHE-1 have been described recently, calcineurin-b
homologue protein-1 and tescalcin,34 both of which bind Ca21
and appear to be crucial in regulating NHE-1 sensitivity to
pHi. In addition, calcineurin-b homologue protein-1 phos-
phorylation was shown to induce NHE-1 inhibition.35 What-
ever the case, we would like to highlight the surprising
magnitude of the SIL effect on NHE-1 activity, because it
almost abolished pHi recovery from the acidic load, an action
comparable only to that seen with high doses of specific
NHE-1 inhibitors.30
The dosage used for chronic SIL treatment was 100 mg
kg21 day21, which may appear to be very high, at least
when compared with that recommended for humans. How-
ever, it was the same dose used by Takimoto et al14 in
mice, and, as also shown by those authors, there was no
evidence of a decrease in blood pressure that could have
affected the conclusions (see Table 2). Takimoto et al36
Figure 4. MI promoted a slight tendency to increase LVEDd and a significant increase in LVESd (A and B). SIL treatment did not
modify LVEDd (A) but prevented the increase in LVESd (B). Thus, fractional shortening (FS) decreased after MI and recovered with SIL
treatment (C). Accordingly, the ratio of the maximum rate of rise of LV pressure divided by the pressure at the moment such maximum
occurs decreased after MI and recovered to control values after SIL treatment (D). None of these parameters was affected by SIL alone
(SHAM1SIL group). *P,0.05 vs all other groups.
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also used an even greater dose in a previous report in mice.
In human beings, SIL promoted modest nitrate-like hemo-
dynamic effects lowering systolic and diastolic blood
pressure.37,38
The measurement of PKG-1 activity and expression per-
formed by us revealed only an increase in PKG-1 activity
after SIL treatment in the post-MI group, which is also in
agreement to the results obtained by Takimoto et al14 in a
mice model of pressure overload–induced hypertrophy,
where PKG-1 activity only increased in hypertrophic-treated
hearts but not in treated shams. As mentioned in that work,
cGMP-dependent signaling pathways seem generally more
potent in hearts under stress, much like an automotive
brake.14 Larger effects of PDE5A inhibition can be seen in the
presence of increased atrial natriuretic peptide stimulation or
NO donors.39 We should keep in mind that the experimental
group subjected to MI showed increased myocardial BNP
levels (Figure 5). However, we cannot explain why chronic
PDE5A inhibition decreased NHE-1 activity even in the
experimental group in which no significant change in PKG-1
activity was detected. In this regard, 2 alternative explana-
tions of these apparently contradictory results should be
examined. First, the PDE5A inhibitor could be acting through
a different mechanism than the increase in PKG-1 activity.
This possibility seems unlikely, given that the PKG-1 inhib-
Figure 6. The increased NHE-1 expression in post-MI hearts
correlated with enhanced NHE-1 activity detected by the higher
maxdpHi/dt after an acidic load vs SHAM. As detected in the
acute experiments (Figure 1), SIL treatment abolished the
NHE-1 activity almost completely in post-MI hearts, as well as
in the treated shams (SHAM1SIL group). As in Figures 1 and 2,
typical experiments plus their best exponential fit for each
group are displayed in A, and the corresponding pooled data
for the maxdpHi/dt are displayed in B. *P,0.05 vs SHAM,
†P,0.05 vs MI.
TABLE 4. Maximal-Induced Intracellular Acidification After
Ammonium Washout and bi for the 4 Experimental Groups
Experimental Groups pHi bi, mmol/L
SHAM (n55) 6.7360.02 28.360.8
MI (n55) 6.7660.02 27.460.7
MI1SIL (n55) 6.7760.03 26.960.9
SHAM1SIL (n54) 6.7460.04 28.560.7
Figure 5. BNP mRNA (A) and NHE-1 protein (B) expression
increased in the MI group. Both effects were inhibited signifi-
cantly by SIL. SIL on shams did not affect BNP or NHE-1
expressions. A representative NHE-1 blot is displayed above
the bar graph. *P,0.05 vs SHAM, †P,0.05 vs MI.
TABLE 3. PKG-1 Activity and Expression After Chronic SIL
Treatment
Experimental Groups
PKG-1 Activity, fmol
PO4 min21 (mg protein)21
PKG-1 Protein
Expression
SHAM (n54) 5.5660.23 1.9660.12
MI (n55) 4.8560.29 1.6260.10
MI1SIL (n55) 6.7360.41* 1.8660.30
SHAM1SIL (n54) 4.9060.28 2.1560.31
PKG-1 protein expression indicates densitometric analysis by immunoblot
referred to that of actine.
*P,0.05 vs other groups.
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itor (KT5823) cancelled the inhibitory effect on NHE-1.
Second, under certain conditions of sustained stress, the
PDE5A inhibitor may increase PKG-1 activity in a subcellu-
lar compartment that is sensed by NHE-1. In this regard,
Castro et al39 reported that cGMP is highly compartmental-
ized in rat cardiomyocytes and that the level of PDEs may be
quite different depending on which intracellular compartment
is measured. In any case, PDE5A inhibition seems to inhibit
NHE-1 and exerts beneficial effects on post-MI remodeling,
similar to what has been reported for NHE-1 inhibitors1,3–7
and for SIL after aortic constriction.14 In line with our
findings are the reports showing that PDE5A inhibition, as
well as the specific NHE-1 blockade, both induced regression
of hypertrophy in pressure-overloaded myocardium.14,27–29
Some limitations of this study deserve to be considered.
First, the IS in our model seems to be relatively small
('30%), and the animals were followed up for only 6 weeks
after the coronary occlusion. This is probably the reason why
cardiac function was only mildly depressed. Whether, with
larger IS or longer follow-up, SIL treatment will show similar
cardioprotective effects and/or prevention of heart failure
similar to the NHE-1 inhibitors5,40 cannot be ascertained from
the present results. Also, although we do know that PDE5A
inhibition by another structurally different compound
(EMD360527/5) also inhibited NHE-1 (see Figure 1), prob-
ably by increasing PKG-1 activity, we do not know whether
other interventions leading to PKG-1 activation by PDE
inhibition or by pathways different to PDE inhibition will
induce similar beneficial effects on myocardial remodeling to
those described here.
Perspectives
The beneficial effect of blocking PDE5A after MI appears to
operate by inhibiting NHE-1 and is manifested by a decrease
in post-MI hypertrophy and remodeling and improvement in
function. Interestingly, the pharmacological intervention did
not alter the steady-state pHi but prevented the increase in
NHE-1 activity after the acidic load, which may result in a
better therapeutic approach than NHE-1 inhibitors. Whether
or not increasing PKG-1 after PDE5A inhibition might
represent an alternate pathway to inhibit NHE-1 that would
not have the adverse effects observed with other NHE
inhibitors needs to be investigated.
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